{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:50:13Z","timestamp":1760061013799,"version":"build-2065373602"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1740","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA has approved Inlexzo, a gemcitabine intravesical system, for treatment of Bacillus Calmette-\nGu\u00e9rin (BCG)-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ, with or\nwithout papillary tumors. The Inlexzo system is placed into the bladder to deliver gemcitabine for 3 weeks.<\/jats:p>","DOI":"10.58347\/tml.2025.1740c","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T20:19:09Z","timestamp":1760041149000},"page":"e176-e177","source":"Crossref","is-referenced-by-count":0,"title":["Intravesical Gemcitabine (Inlexzo) for Bladder Cancer"],"prefix":"10.58347","volume":"67","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"37151","published-online":{"date-parts":[[2025,10,27]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T20:19:09Z","timestamp":1760041149000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1740c"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":0,"journal-issue":{"issue":"1740","published-online":{"date-parts":[[2025,10,27]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2025.1740c","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]}}}